ARCH Venture Partners IX, L.P.
10% owner at Vir Biotechnology; 10% owner at Lyell Immunopharma; 10% owner at Boundless Bio.
- Rank
- 804th of 809
- Companies held
- 1
- Largest holding
- VIR, 100.0% of total
- Latest SEC filing
- Jul 1, 2026
- Listed but not counted
- $71.3M
What the $50.7M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Vir Biotechnology VIR Common Stock | Indirectly (see filing footnote) | 5,626,008 | $8.87 | $49.9M | 98.4% | Form 4, Sep 6, 2022 |
| Vir Biotechnology VIR Common Stock | Indirectly (see filing footnote) | 61,160 | $8.87 | $542K | 1.1% | Form 4, Sep 6, 2022 |
| Vir Biotechnology VIR Common Stock | Directly | 30,570 | $8.87 | $271K | 0.5% | Form 4, Sep 6, 2022 |
Share counts are the amounts ARCH Venture Partners IX, L.P. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on ARCH Venture Partners IX, L.P.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Vir Biotechnology VIR Common Stock | Through ARCH Venture Fund IX, L.P. Held by a company or fund the insider manages | 5,865,567 | $8.87 | $52.0M | — | Form 4, Sep 2, 2022 |
| Lyell Immunopharma LYEL Common Stock | Through ARCH Venture Fund IX, L.P. Held by a company or fund the insider manages | 910,317 | $13.58 | $12.4M | — | Form 4, Jul 25, 2025 |
| Boundless Bio BOLD Common Stock | Through AVP X Overage LP Held by a company or fund the insider manages | 1,181,766 | $2.38 | $2.8M | — | Form 4, Jul 1, 2026 |
| Boundless Bio BOLD Common Stock | Through ARCH Venture Fund IX Overage, L.P. Held by a company or fund the insider manages | 828,570 | $2.38 | $2.0M | — | Form 4, Jul 1, 2026 |
| Boundless Bio BOLD Common Stock | Through ARCH Venture Fund IX, L.P. Held by a company or fund the insider manages | 683,759 | $2.38 | $1.6M | — | Form 4, Jul 1, 2026 |
| Vir Biotechnology VIR Common Stock | Through ARCH Venture Fund IX Overage, L.P. Held by a company or fund the insider manages | 57,912 | $8.87 | $514K | — | Form 4, Sep 2, 2022 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 801 | Insight Satellite Co-Invest, L.P. 10% owner, HawkEye 360 | $51.0M |
| 802 | MSD Partners, L.P. Director, Hayward Holdings | $51.0M |
| 803 | Champion River Ventures Ltd 10% owner, Niagen Bioscience | $50.9M |
| 804 | ARCH Venture Partners IX, L.P. 10% owner, Vir Biotechnology | $50.7M |
| 805 | Summer Road LLC 10% owner, Ocular Therapeutix | $50.3M |
| 806 | OCM Growth Holdings LLC 10% owner, Runway Growth Finance | $50.3M |
| 807 | Regal Planet Ltd 10% owner, CURRENC Group | $50.3M |
Other Vir Biotechnology insiders
All VIR insiders- George A. Scangos$23.6MDirector. #3690 overall
- Vicki L. Sato$9.6MDirector. #7843 overall
- Backer Marianne De$9.4MPresident and CEO. #8333 overall
- Robert Nelsen$5.5MDirector. #13445 overall
- Phillip A. Sharp$1.5MDirector. #2946 overall
- Ramy Farid$284KDirector. #8182 overall
Questions
How much stock does ARCH Venture Partners IX, L.P. own?
ARCH Venture Partners IX, L.P. holds $50,716,336 in listed stock based on SEC filings and current prices, mostly Vir Biotechnology (VIR). That ranks 804th on the Stock Rich List.
Is this ARCH Venture Partners IX, L.P.'s net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did ARCH Venture Partners IX, L.P. last buy or sell stock?
The most recent open-market trade on file is a sale of 16,000 BOLD shares on Jul 1, 2026 at $2.49.
Files jointly with Keith Crandell, Robert Nelsen, SEC filer 1219043.